We are recruiting women in Canada with type 1 diabetes who are currently pregnant or have been pregnant for a research study. We are asking women to participate in interviews to discuss their experiences and challenges while living with type 1 diabetes during pregnancy. Eligible participants from anywhere in Canada will be invited to take part in a focus group remotely over Zoom. Participation in this study will require about 1-2 hours.

Each person’s experience with multiple sclerosis (MS) is different. These differences are likely due to a mix of factors. Examples of some of these factors are a person’s sex, gender, age, ethnicity, and if they live in a city or not. Together, these factors contribute to a person’s diversity. Past MS research has not included people who are diverse. Yet some diversity factors can affect the health of a person with MS. Currently, researchers are unsure which diversity factors affect health the most. This in turn limits access to the right types of support and care. The purpose of this study is to find out how genes, diversity traits, and life experiences affect the health of people with MS compared to people without MS. The study’s long-term goal is to improve health in people with MS who have not been included in past research. If you agree to participate, you will be asked to complete 4 phone interviews that are 60-90 minutes long, each one year apart. The interview will ask questions about your diversity traits and your physical, emotional, and social health and function. The interviewer will also assess your physical and mental function. You will also give a saliva sample by mail. You will be compensated for your time.

This study is being done to learn more about the tolerability, safety and efficacy of a medicine called EMPAgliflozin in children and adolescents with chronic kidney disease (CKD). For the first 24 weeks, some children will receive empagliflozin, and others will receive a placebo (a pill with no medication in it). After the first 24 weeks, all children will have the option to receive empagliflozin for an additional 48 weeks. The entire study will last up to 80 weeks for each child. The medication is a pill taken by mouth, twice a day. Participants in the study will come to the Stollery Hospital approximately once a month for a year and a half.

We are doing a Canada-wide survey to learn about the nutrition and health of Black adults living in Canada. We want to understand what helps or makes it harder for Black people to eat well and stay healthy, including access to healthy and culturally familiar foods, food affordability, physical activity, sleep, and access to healthcare. We will also ask about everyday experiences that may affect health, such as stress or unfair treatment. The information you share will help researchers and community partners better understand the needs and priorities of Black communities and support future programs, services, and policies that improve health and nutrition for Black people in Canada. The survey takes about 25–30 minutes to complete, and participants will receive a $25 gift card as a thank-you for their time.

Somatostatin analogs are first line treatment for patients with metastatic neuroendocrine tumours (NET). There are currently two different types of somatostatin analogs available: octreotide LAR and lanreotide. Both are given to patients as injections every four weeks. Octreotide LAR is given as a deep injection into the muscle (intramuscular or IM injection) whereas lanreotide is given under the skin (subcutaneous or SC injection). While both medications have been shown to benefit patients with metastatic NET, we don't know if one works better than the other, as there has been no high quality research comparing them head to head. Some smaller studies have suggested that there might be an advantage of lanreotide over octreotide LAR since giving the octreotide injection is technically more difficult and can end up in the wrong spot, resulting in the patient not getting full benefit of the medication. Furthermore, lanreotide has improved convenience for patients. With its simpler SC administration protocol, lanreotide can be given at home by patients/caregivers, while octreotide must be given by a trained nurse. The goal of our study is to compare outcomes for patients taking lanreotide with patients taking octreotide LAR. We will look at outcomes related to their cancer ( i.e. how well their symptoms are controlled and how long it takes for their cancer to progress) as well as their quality of life and perspectives about the treatment. Our results are expected to reveal whether two different somatostatin analogues, which are used interchangeably in NET treatment, differentially impact clinical outcomes and/or patient experiences.

This study uses special sound waves, called low intensity frequency ultrasound to gently affect small areas of the brain for a short time. There is no surgery involved, and it is safe to use. By watching how a person moves during tasks before and after the sound waves are used, we can learn how the brain helps control movement. In the future, this research might help create better treatments for conditions like Parkinson’s disease.

This study is for children aged between 2 and 18 years who have Lennox-Gastaut Syndrome or Dravet Syndrome taking artisanal CBD to take part in a 20-week long clinical research study. The primary purpose is to investigate the best way to transition these children from artisanal CBD to a pharmaceutical-grade version of CBD called Epidiolex.

This study is evaluating an investigational treatment for Eosinophilic Esophagitis (EoE) called EP-104GI, which may help reduce inflammation and improve symptoms. EP-104GI is a long-acting injectable corticosteroids [fluticasone propionate] to be injected directly into the esophagus during an Endoscopy procedure.

This study is evaluating a new wearable heart monitor called HeartWatch. The goal is to see whether it records heart rhythm information as well as standard heart monitors that are currently used in clinics. People whose doctor has recommended, or may recommend, a heart monitor to check their heart rhythm may be able to take part. Participants in the study will wear the conventional heart monitor that is prescribed as part of their usual care. They will also wear the HeartWatch device so that researchers can compare the recordings from the two devices. The HeartWatch device is worn on the upper arm using a band. It continuously records heart rhythm data.

Many people with depression do not get better with the standard treatments. Ketamine treatment has become a strong and hopeful therapy for this kind of depression. Experts know that ketamine can help unipolar and bipolar treatment resistant depression. But, some questions remain. Ketamine treatment can make you feel disconnected from your body (dissociation effects). Some people may also abuse ketamine and develop an addiction. As such, more research is needed about dissociation effects and addiction potential. So, we are doing this study to learn more about the benefits and risks of ketamine treatment.